These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26594728)

  • 1. HPV vaccines and pregnancy.
    Prescrire Int; 2015 Oct; 24(164):239-40. PubMed ID: 26594728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy.
    Forinash AB; Yancey AM; Pitlick JM; Myles TD
    Ann Pharmacother; 2011 Feb; 45(2):258-62. PubMed ID: 21285408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV vaccines and pregnancy: the situation in early 2012.
    Prescrire Int; 2012 Jun; 21(128):154-7. PubMed ID: 22822594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
    Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
    J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.
    Angelo MG; Taylor S; Struyf F; Tavares Da Silva F; Arellano F; David MP; Dubin G; Rosillon D; Baril L
    Expert Rev Vaccines; 2014 Nov; 13(11):1297-306. PubMed ID: 25219284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.
    Scheller NM; Pasternak B; Mølgaard-Nielsen D; Svanström H; Hviid A
    N Engl J Med; 2017 Mar; 376(13):1223-1233. PubMed ID: 28355499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing human papillomavirus vaccine efficacy and safety.
    Hendrix SL
    J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy.
    Faber MT; Duun-Henriksen AK; Dehlendorff C; Tatla MK; Munk C; Kjaer SK
    Vaccine; 2019 Jan; 37(2):265-271. PubMed ID: 30503078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.
    Baril L; Rosillon D; Willame C; Angelo MG; Zima J; van den Bosch JH; Van Staa T; Boggon R; Bunge EM; Hernandez-Diaz S; Chambers CD
    Vaccine; 2015 Nov; 33(48):6884-91. PubMed ID: 26206268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.